Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.58 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.53 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.53 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8924354 | 1.00 | ADORA2A (0.80) | ADORA2AADORA3ADORA1PRMT5METTL3 | |
| SCHEMBL10456342 | 0.95 | ADORA2A (0.80) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL14367724 | 0.95 | ADORA2A (0.80) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL10455994 | 0.94 | ADORA2A (0.76) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL13612127 | 0.94 | ADORA2A (0.76) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL12547192 | 0.94 | ADORA2A (0.78) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL13020932 | 0.94 | ADORA2A (0.78) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL8922576 | 0.94 | ADORA2A (0.78) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL10456127 | 0.92 | ADORA2A (0.70) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL13612217 | 0.92 | ADORA2A (0.70) | ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213541-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATING RECURRENT TUMOR GROWTH | ADENOSINE THERAPEUTICS, LLC (US) | 2014-07-31 | — | — | US | disclosed |
| US-8551972-B2 | Agonists of A2A adenosine receptors for treating recurrent tumor growth | ADENOSINE THERAPEUTICS, LLC (US) | 2013-10-08 | — | — | US | disclosed |
| US-8222228-B2 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2012-07-17 | — | — | US | disclosed |
| US-8178509-B2 | Method to treat sickle cell disease | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110166094-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATING RECURRENT TUMOR GROWTH | PGXHEALTH, L.L.C. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110136755-A1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110091385-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | PGXHEALTH, LLC (US) | 2011-04-21 | — | — | US | disclosed |
| US-7888329-B2 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | PGXHEALTH, LLC (US) | 2011-02-15 | — | — | US | disclosed |
| US-7589076-B2 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | PGX HEALTH, LLC (US) | 2009-09-15 | — | — | US | disclosed |
| US-20080009460-A1 | METHOD TO TREAT SICKLE CELL DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-01-10 | — | — | US | disclosed |
| US-20070270373-A1 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | ADENOSINE THERAPEUTICS, LLC | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213541-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATING RECURRENT TUMOR GROWTH | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885ADORA1 3/4885 |
| US-20080009460-A1 | METHOD TO TREAT SICKLE CELL DISEASE | PDE4A, ADORA2A, PDE4B | ADORA2A 2/4885ADORA3 13/4885ADORA1 18/4885 |
| US-20110136755-A1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885ADORA1 3/4885 |
| US-20110091385-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA1 2/4885 |
| US-20110166094-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATING RECURRENT TUMOR GROWTH | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885ADORA1 3/4885 |
| US-20070270373-A1 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.